DRUG on Nasdaq
BRIGHT MINDS BIOSCIENCES INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
-2.8MNet income, fiscal 20242
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
-50.6%Return on equity2
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Consulting fees | 115.0K CAD | 98.4K CAD | 207.4K CAD |
| Directors compensation | 497.3K CAD | 493.8K CAD | 1.2M CAD |
| Foreign exchange | -188.8K CAD | 9.3K CAD | -14.2K CAD |
| Marketing, advertising, and investor relations | 429.7K CAD | 41.6K CAD | 119.4K CAD |
| Office and administrative | 784.1K CAD | 264.0K CAD | 278.8K CAD |
| Professional fees | 739.4K CAD | 547.8K CAD | 437.7K CAD |
| Regulatory and filing | 287.6K CAD | 197.2K CAD | 186.7K CAD |
| Research and development | 11.1M CAD | 1.2M CAD | 5.0M CAD |
| Loss before other items | -13.7M CAD | -2.8M CAD | -7.4M CAD |
| Interest income | 1.5M CAD | 30.1K CAD | 0 CAD |
| Net and comprehensive loss | -12.2M CAD | -2.8M CAD | -7.4M CAD |
| Basic and diluted loss per share (in CAD per share) | -1.78 CAD | -0.65 CAD | -1.98 CAD |
| Weighted average number of common shares outstanding basic and diluted (in shares) | 6.9M shares | 4.3M shares | 3.7M shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Cash and cash equivalents | 82.9M CAD | 5.7M CAD | 6.7M CAD |
| Sales tax receivables | 209.9K CAD | 50.2K CAD | |
| Interest receivables | 203.2K CAD | 0 CAD | |
| Prepaids | 2.6K CAD | 216.6K CAD | |
| Current assets | 84.3M CAD | 6.0M CAD | |
| Right-of-use asset | 112.0K CAD | 117.7K CAD | 66.4K CAD |
| TOTAL ASSETS | 84.4M CAD | 6.1M CAD | |
| Accounts payable and accrued liabilities | 2.3M CAD | 449.3K CAD | |
| Lease liability current portion | 84.5K CAD | 79.4K CAD | |
| Current liabilities | 913.1K CAD | 528.7K CAD | |
| Lease liability non-current portion | 41.2K CAD | 39.6K CAD | |
| TOTAL LIABILITIES | 2.4M CAD | 568.3K CAD | |
| Share capital | 123.2M CAD | 35.4M CAD | |
| Pre-funded warrants | 0 CAD | 455.6K CAD | |
| Reserves | 5.4M CAD | 4.0M CAD | |
| Deficit | -46.6M CAD | -34.3M CAD | |
| TOTAL SHAREHOLDERS EQUITY | 82.0M CAD | 5.5M CAD | 6.6M CAD |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 84.4M CAD | 6.1M CAD |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net loss | -12.2M CAD | -2.8M CAD | -7.4M CAD |
| Depreciation right-of-use asset | 76.9K CAD | 73.4K CAD | 72.5K CAD |
| Foreign exchange | -312.7K CAD | -10.1K CAD | 45.3K CAD |
| Interest expense | 35.9K CAD | 8.9K CAD | 19.8K CAD |
| Share-based compensation | 3.2M CAD | 839.8K CAD | 1.2M CAD |
| Sales tax receivables | -159.7K CAD | -13.2K CAD | 77.5K CAD |
| Interest and other receivables | -203.2K CAD | 0 CAD | 41.3K CAD |
| Prepaids | -771.3K CAD | -188.9K CAD | 136.7K CAD |
| Accounts payable and accrued liabilities | 1.7M CAD | 242.0K CAD | -1.2M CAD |
| Net cash used in operating activities | -8.7M CAD | -1.9M CAD | -7.0M CAD |
| Private placement proceeds | 82.1M CAD | 900.0K CAD | 1.2M CAD |
| Share issuance costs | -360.1K CAD | 0 CAD | -27.0K CAD |
| Pre-funded warrant issuance proceeds | 0 CAD | 0 CAD | 831.8K CAD |
| Option exercise proceeds | 1.3M CAD | 0 CAD | 0 CAD |
| Pre-funded warrant and warrant exercise proceeds | 2.6M CAD | 302 CAD | 253.4K CAD |
| Principal portion of lease liability | -100.2K CAD | -89.7K CAD | -86.1K CAD |
| Net cash from financing activities | 85.6M CAD | 810.6K CAD | 2.2M CAD |
| Change in cash and cash equivalents | 76.9M CAD | -1.0M CAD | -4.8M CAD |
| Effect of foreign exchange on cash | 312.6K CAD | 11.7K CAD | -45.3K CAD |
| Fair value of RSUs exercised | 900.2K CAD | 232.5K CAD | 232.5K CAD |
| Fair value of Pre-funded warrants exercised | 455.6K CAD | 0 CAD | 0 CAD |
| Fair value of options exercised | 862.8K CAD | 0 CAD | 0 CAD |
Recent filings
- Oct 2, 20266-K
- Oct 1, 20266-K
- Aug 17, 20266-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 2026S-8
- Aug 12, 2026SCHEDULE 13G/A
- Jul 2, 2026SCHEDULE 13D/A
- Jun 3, 20266-K
- Jun 2, 20266-K
- May 28, 20266-K
- May 20, 20266-K
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- May 12, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7